SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

Molecular Imaging and Biology

Volumn 17, Issue 3, 2015, Pages 313-318

  Kratochwil, C ^a   Stefanova, M ^a   Mavriopoulou, E ^a   Holland Letz, T ^b   Dimitrakopoulou Strauss, A ^b   Afshar Oromieh, A ^a   Mier, W ^a   Haberkorn, U ^a   Giesel, F L ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Neuroendocrine tumors; Peptide related radionuclide therapy; Somatostatin receptor; SUV; 68Ga DOTATOC

Indexed keywords

CONTRAST MEDIUM; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR SUBTYPE 2, HUMAN;

AGED; ANALOGS AND DERIVATIVES; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROBABILITY; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; SECONDARY;

AGED; CONTRAST MEDIA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROBABILITY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84939876640     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0795-3     Document Type: Article

References (16)

1. Rinke A, Muller HH, Brittinger CS et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663
2. Modlin IM, Oberg K, Chung DC et al (2008) Gastroeneteropancreatic neuroendocrine tumors. Lancet Oncol 9:61–72
3. Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine tumors. Cancer 117:268–275
4. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523
5. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513
6. Van Essen M, Krenning EP, De Jong M et al (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723–734
7. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastropancreatic tumors. J Clin Oncol 23:2754–2762
8. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin- receptor–mediated radionuclide therapy. J Nucl Med 50:1427–1434
9. Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52
10. Оtte A, Mueller-Brand J, Dellas S et al (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418
11. Giesel FL, Kratochwil C, Mehndiratta A et al (2012) Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 81:2820–2825
12. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130
13. Campana D, Ambrosini V, Pezzilli R et al (2010) Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 51:353–359
14. Koukouraki S, Strauss LG, Georgoulias V et al (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466
15. Pfeifer AK, Gregersen T, Grønbæk H et al (2011) Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93:189–196
16. Haug A, Auernhammer CJ, Wängler B (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770